VisEn Medical, Inc.

VisEn Medical Appoints Janet Lankard as Vice President of Sales and Technology Collaborations

VisEn Medical Appoints Janet Lankard as Vice President of Sales and Technology Collaborations

January 24, 2006

CAMBRIDGE, Mass., Jan. 24 /PRNewswire/ -- VisEn Medical today announced that it has appointed Janet Lankard as Vice President of Sales and Technology Collaborations. This newly created position significantly enhances VisEn's commercialization of its proprietary Fluorescence Molecular Tomography (FMT) system and optical imaging probe portfolio. In addition, Janet's efforts will also support advanced application-based partnerships with pharmaceutical and academic leaders in the field. Ms.

Zalicus

CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Study Results in Hand Osteoarthritis

CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Study Results in Hand Osteoarthritis

January 30, 2006

Trial Meets Primary Endpoint with Statistically Significant Reduction in Pain

IntelliVid

CVS Expands Use of IntelliVid's Intelligent Video Analysis Solution to Reduce Shrink

CVS Expands Use of IntelliVid's Intelligent Video Analysis Solution to Reduce Shrink

February 13, 2006

CAMBRIDGE -- IntelliVid Corporation, the leader in intelligent video analysis software for retail loss prevention, today announced that CVS , the country's largest drugstore chain with 5,461stores in 37 states, has expanded the use of its Video Investigator™ software in several regions.

After piloting IntelliVid's technology in one high-risk store in the Boston area, CVS has now installed Video Investigator in several stores throughout the country.

BG Medicine, Inc.

TB Alliance and BG Medicine Initiate Biomarker Discovery Program

TB Alliance and BG Medicine Initiate Biomarker Discovery Program

February 21, 2006

Project Aims to Streamline and Shorten Drug Development for Tuberculosis

New York, NY and Waltham, MA., February 21, 2006 — The Global Alliance for TB Drug Development (TB Alliance) and BG Medicine Inc. announced today a collaboration to identify biomarkers for drug efficacy in the treatment of tuberculosis (TB), a step toward faster and more efficient drug development.

e-Dialog, Inc.

British Airways Selects e-Dialog as Preferred E-mail Communications Provider

British Airways Selects e-Dialog as Preferred E-mail Communications Provider

March 1, 2006

LONDON & LEXINGTON, Mass.--(BUSINESS WIRE)--March 1, 2006--British Airways has completed a competitive tender process and appointed e-Dialog as its e-mail marketing service provider for customer communications in the UK.

e-Dialog will provide British Airways with strategic and technological expertise and support for its e-mail communications to Executive Club members and registered customers on its Web site, www.ba.com.

TransMedics, Inc.

TransMedics, Inc., Makers of the First Device to Maintain Functioning Organs Outside the Body, Raises $29.75 Million in Series C Funding Led by 3i

TransMedics, Inc., Makers of the First Device to Maintain Functioning Organs Outside the Body, Raises $29.75 Million in Series C Funding Led by 3i

March 14, 2006

ANDOVER, Mass.--(BUSINESS WIRE)--March 14, 2006--TransMedics, Inc., a privately held medical device company founded in 1998 to address the unmet need for better, more effective organ transplant technologies, announced today that it has raised $29.75 million in Series C financing. The company's breakthrough, investigational technology, the Organ Care System, is the first organ transport system designed to maintain organs in a warm, functioning state outside of the body to optimize their health, enabling living organ transplant.

Morphotek, Inc.

Morphotek Announces Appointments and Promotions To Management Team

Morphotek Announces Appointments and Promotions To Management Team

March 13, 2006

Exton, PA, March 13, 2006 -- Morphotek®, Inc. announced today the appointment of Robert Radie as Chief Business Officer and the promotion of Dr. Luigi Grasso to Senior Vice President of Research & Development. These advancements are at a time that the company moves forward with its broad therapeutic antibody pipeline through clinical trials and continues to market its human antibody platform technology to support internal product development and collaborative alliances.

Helicos BioSciences Corporation

Helicos BioSciences Announces $40 Million Funding Round

Helicos BioSciences Announces $40 Million Funding Round

March 15, 2006

Pioneer in High-Speed, High-Sensitivity Sequencing Receives Major Investment from Top-Tier Venture Capital Firms in Support of "true Single Molecule Sequencing" (tSMS(TM)) Technologies and Techniques

Interactive Supercomputing Corporation

Star-P named “Most Significant New High Performance Computing Software”

Star-P named “Most Significant New High Performance Computing Software”

November 14, 2006

Wins HPCwire’s 2006 Editors’ Choice Award

TAMPA, Fla., Nov. 14, 2006 – Interactive Supercomputing’s (ISC) Star-P™ software won the HPCwire 2006 Editors’ Choice Award for Most Significant New HPC Software Product. The award, announced yesterday at the SC06 international conference, is widely recognized as the most prestigious in the technical computing industry.

Zalicus

CombinatoRx Announces Closing of $48.0 Million Private Placement

CombinatoRx Announces Closing of $48.0 Million Private Placement

March 24, 2006

BOSTON--(BUSINESS WIRE)--March 24, 2006--CombinatoRx, Incorporated (NASDAQ: CRXX - News), today announced that it has closed the previously announced private placement of approximately 4.68 million shares of common stock at a price of $10.25 per share for a total purchase price of $48.0 million. Cowen & Co. LLC served as exclusive placement agent for the transaction. Pacific Growth Equities, LLC acted as financial advisor.